Enterprise Value

193.1M

Cash

343M

Avg Qtr Burn

-29.92M

Short % of Float

0.00%

Insider Ownership

8.45%

Institutional Own.

76.89%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
obe-cel (AUTO1) (CD19) Details
Acute lymphoblastic leukemia, Cancer, Blood cancer

BLA

Submission

AUTO4 Details
Peripheral T cell cancer

Phase 1/2

Data readout

obe-cel (AUTO1) (CD19) Details
Non-Hodgkin lymphoma, Cancer, Leukemia, Lymphoma, Chronic lymphocytic leukemia

Phase 1

Data readout

obe-cel (AUTO1) (CD19) Details
Primary CNS lymphoma (central nervous system)

Phase 1

Data readout

Phase 1

Data readout

AUTO1/22 (CD19 & CD22) Details
Cancer, Leukemia, Acute lymphoblastic leukemia

Phase 1

Update

AUTO5 Details
T-cell lymphoma

Phase 1

Initiation

AUTO6NG Details
Solid tumor/s, Neuroblastoma

Phase 1

Initiation

AUTO3 (CD19, CD22) Details
Lymphoma, Diffuse large B cell lymphoma, Cancer

Failed

Discontinued